Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
Titel:
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
Auteur:
Zaman, Khalil Winterhalder, Ralph Mamot, Christoph Hasler-Strub, Ursula Rochlitz, Christoph Mueller, Andreas Berset, Catherine Wiliders, Hans Perey, Lucien Rudolf, Christine Biaggi Hawle, Hanne Rondeau, Stephanie Neven, Patrick